Merck MRK announced that EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended granting conditional ...

Neoadjuvant therapy for high-risk renal cell carcinoma (RCC) may offer a survival advantage over adjuvant therapy, according to data presented at the 2024 annual meeting of the Society of Urologic ...

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

LUGPA annual meeting, Gautam Jayram, MD, reviewed important developments therapeutics and diagnosis and staging.

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock ...

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

Top Forbes SHOOK advisors pledge $1.5M to fund kidney cancer treatment at Sloan Kettering Cancer Center in New York ...

Weill Cornell Medicine has received a four-year, $1.4 million grant from the U.S. Department of Defense to investigate a new therapeutic approach for ...

Brandy Verdin, 49, lives with her husband in Gray, Louisiana. She was diagnosed with Stage IV renal cell carcinoma in May 2023.

SUO annual meeting included a kidney cancer session, featuring a presentation by Dr. Nicholas Kavoussi discussing artificial ...